Acute graft versus host disease in intestine – European Clinical Trials Information Network

Study on MaaT013 for Treating Acute Gastrointestinal Graft-Versus-Host Disease in Patients Not Responding to Ruxolitinib

Wed, 29 Apr 2026 15:01:43 +0000

This clinical trial is focused on studying a condition known as acute graft-versus-host disease (aGVHD), which affects the gastrointestinal (GI) tract. This condition can occur in patients who have undergone a stem cell transplant and involves the donor cells attacking the patient’s body. The trial is specifically for patients whose aGVHD is resistant or intolerant to a medication called ruxolitinib. The treatment being tested in this study is called MaaT013, which is a rectal solution containing a mixture of healthy bacteria from donor stool, known as allogeneic faecal microbiota.

The purpose of the study is to evaluate how effective MaaT013 is in treating aGVHD in the GI tract. Participants in the study will receive the treatment over a period of 28 days. The study will monitor the response of the disease to the treatment at various points, including day 28, day 56, and three months after starting the treatment. The study will also look at the safety of MaaT013 and how it affects the overall health and survival of the participants.

Throughout the study, researchers will assess how well the treatment works in reducing the symptoms of aGVHD and improving the patients’ quality of life. The study will also track the duration of the response to the treatment and any changes in the patients’ condition over time. The goal is to find out if MaaT013 can be a successful treatment option for patients with aGVHD who have not responded well to other treatments.

Study on Long-Term Safety of Ruxolitinib, Panobinostat, and Siremadlin for Patients Continuing Treatment from Previous Studies

Wed, 29 Apr 2026 14:59:37 +0000

This clinical trial is focused on evaluating the long-term safety of treatments for patients who have previously participated in studies involving the medication ruxolitinib, either alone or in combination with other drugs. Ruxolitinib is a medication used to treat certain types of blood disorders. In this study, it may be combined with other medications such as panobinostat, siremadlin (also known as HDM201), or rineterkib. The purpose of the study is to gather information on the safety of these treatments over a longer period.

Participants in this study will continue their treatment with ruxolitinib or its combinations as they have been doing in their previous studies. The study will monitor the frequency and severity of any side effects or adverse events that occur during the treatment. This information will help researchers understand the long-term safety of these medications and their combinations.

The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. It is conducted at multiple centers, allowing for a diverse group of participants. The study aims to provide valuable data on the safety of these treatments, which can benefit future patients who may receive these medications. Participants will be assessed regularly to determine any clinical benefits they may experience from the continued treatment.

Study on the Safety and Effectiveness of Apraglutide for Patients with Steroid-Resistant Gastrointestinal Acute Graft Versus Host Disease

Wed, 29 Apr 2026 14:29:43 +0000

This clinical trial is focused on studying a condition known as Acute Graft Versus Host Disease (aGVHD), which can occur after a stem cell or bone marrow transplant. The trial is investigating the safety and effectiveness of a treatment called apraglutide, which is a powder that is mixed into a solution and given as an injection under the skin. The study is specifically looking at patients who have aGVHD that affects the gastrointestinal tract and does not respond to standard steroid treatments.

The purpose of the study is to evaluate how well apraglutide works and how safe it is for patients with this type of aGVHD. Participants in the study will receive either apraglutide or a placebo, in addition to their current best available therapy. The study will monitor participants over a period of time to observe any changes in their condition and to check for any side effects. The trial will also assess how the treatment affects the overall health and recovery of the participants.

Throughout the study, participants will have regular check-ups to track their progress and any potential side effects. The trial aims to provide valuable information on whether apraglutide can be a beneficial treatment option for patients with steroid-refractory gastrointestinal aGVHD. The study is expected to continue until 2025, allowing researchers to gather comprehensive data on the treatment’s impact.